Whether compounded semaglutide is "legal" doesn't have a permanent yes-or-no answer — it depends on rules that have changed several times, and are still changing. The short version as of 2026: the special exception that made compounded GLP-1s widely legal has closed, and access is now tightly restricted. Here's the honest, plain-English picture.

In plain terms: it was broadly legal during a drug shortage; that shortage is over, so the legal basis has largely gone away.

First, what "compounding" means

Compounding is when a licensed pharmacy prepares a medication itself, rather than dispensing the finished product a drug company makes. For GLP-1s, that usually means a vial of semaglutide or tirzepatide prepared by the pharmacy instead of a branded pre-filled pen. The intended active ingredient is the same GLP-1 molecule — compounding describes *who prepared it and how*, not a different drug. (More on that in compounded vs brand GLP-1.)

The two kinds of compounding pharmacy: 503A and 503B

US law defines two categories, named after sections of the federal law:

  • 503A — traditional pharmacies that compound for an individual patient, typically against a prescription.
  • 503B — larger "outsourcing facilities" that make bigger batches under stricter manufacturing standards.

Both are only allowed to compound certain drugs under certain conditions. A widely available brand-name drug generally can't be freely compounded — with one big exception.

The exception that opened the door: drug shortages

Here's the crux. US law allows compounding of a drug that appears on the FDA's official drug-shortage list. The logic is patient access: if the approved product can't meet demand, compounders can help fill the gap.

That is exactly what happened with GLP-1s. Demand exploded, and:

  • Semaglutide and tirzepatide were added to the FDA shortage list during 2022–2024.
  • While they sat on that list, compounding them was permitted — which is why compounded GLP-1s appeared everywhere during those years.

In plain terms: the shortage is the whole reason compounded semaglutide became broadly legal in the first place.

Then the shortages ended

Supply caught up, and the FDA declared the shortages resolved:

  • Tirzepatide — December 2024.
  • Semaglutide — February 2025.

When a drug comes off the shortage list, the legal basis for compounding it goes away too. The FDA set phased wind-down deadlines for pharmacies to stop1.

In plain terms: once the shortage was declared over, the exception that made compounding legal switched off.

The 2026 picture: restricted, and still moving

As of 2026 the situation is narrow. Beyond simply ending the shortage exception, the FDA moved to keep these drugs off the routine compounding lists: in 2026 it proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need to compound them from bulk substances now that supply is stable2. That further narrows any remaining legal room.

There are still narrow, situation-specific reasons a clinician and pharmacy might compound (for example, a documented need for a formulation the branded product doesn't offer) — but the broad, shortage-driven legality of 2022–2024 is gone.

Why this page won't give a permanent answer

This is a genuinely non-static topic. It has changed direction more than once in three years, and it can change again — a new shortage, a court ruling, or a final FDA decision could all move it. So the honest guidance is a method, not a verdict:

  • The status depends on the current FDA shortage list and the current bulks-list decisions — both public.
  • Check the current FDA position rather than relying on any article's snapshot (including this one).
  • Legality also varies with the pharmacy category (503A vs 503B) and the clinical circumstances.

This page explains the public regulatory facts and takes no position on sourcing, suitability, or where anyone should obtain anything — those are matters for a clinician and current law, outside the scope of an educational reference.

The short version

Compounded semaglutide was broadly legal in 2022–2024 because semaglutide was on the FDA drug-shortage list, which permits compounding. Those shortages were declared resolved (tirzepatide December 2024, semaglutide February 2025), and the FDA has since moved to keep these drugs off the routine compounding lists — so as of 2026 the status is restricted and still evolving. Check the current FDA status; this is education, not legal or medical advice.